Basic and clinical studies were conducted on cefclidin (CFCL) which is a newly developed intravenously injectable cephalosporin. The results were as follows. 1) The MICs of CFCL and the control drugs, i:e., cefotaxime (CTX), ceftazidime (CAZ) and cefoperazone (CPZ) against various clinical isolates were determined in accordance with the standard method established by the Japan Society of Chemotherapy. The MIC90s of CFCL for Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus vulgaris, Proteus mirabilis, Citrobacter spp. and Pseudomonas aeruginosa were 12.5, > 100, 0.20, 0.20, 0.78, 0.20 1.56, 0.39, 0.39, 3.13 and 12.5 µg/ml, respectively. The antibacterial activity of CFCL against S.aureus was compatible to that of CAZ but inferior to those of CTX and CPZ. The antibacterial activity of CFCL against E. cloacae and Citrobacter spp. was superior to the activities of CTX, CAZ and CPZ. In particular, the antibacterial activity of CFCL against P. aeruginosa was distinctly more potent than those of CTX, CAZ and CPZ. 2) CFCL was used in the treatment of 5 patients (3 patients with pneumonia, 1 with pulmonary abscess, and 1 with acute bronchitis). CFCL was injected i.v. in a daily dosage of 2.0g-4.0g for 9-21 days, and the clinical response was good in 4 cases and poor in 1. P. aeruginosa and Bacteroides intermedins were isolated as causative bacteria and P. aeruginosa was eradicated, but B intermedins persisted. Neither adverse reactions nor abnormal laboratory change were observed.
|出版ステータス||出版済み - 9月 1992|
!!!All Science Journal Classification (ASJC) codes